Respire_final-01
  • CORPORATE
    • Company Overview
    • Board of Directors
    • RespireRx Organization Structure
    • Social Media Guidelines
  • NEUROTRANSMISSION
  • RESOLUTIONRX
    • Cannabinoid Platform Summary
    • Pharmaceutical Cannabinoids
    • Obstructive Sleep Apnea
    • Dronabinol for the Treatment of Obstructive Sleep Apnea
    • Regulatory Process
  • ENDEAVOURRX
    • Neuromodulators
    • Ampakines
      • AMPAkine Platform Summary
      • Lead Compounds
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • Spinal Cord Injury (SCI)
    • GABAkines
      • GABAkines Platform Summary
      • Background
      • Epilepsy
      • Pain
  • PRODUCT PIPELINE
  • INVESTORS
    • Investor Contact
    • SEC Reports
    • News
    • FAQs
    • Presentations
  • CONTACT

RespireRx Pharmaceuticals Inc. is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

In the News

08/8/22 – RespireRx Pharmaceuticals Inc. Announces that Sleep Review has Discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition

August 8, 2022j3ff1

05/24/22 – RespireRx Pharmaceuticals Inc. Announces that Dr. Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit

May 24, 2022j3ff1

5/17/22 – RespireRx Pharmaceuticals Inc. Announces RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics

May 17, 2022j3ff1
All News

WATCH: RespireRx Interim CEO Arnold Lippa Presents Data at 2022 GRI Virtual Conference

Watch

WATCH: RespireRx Interim CEO Arnold Lippa Discusses Provisional Patent Application for a Novel Lipid-Based Formulation Technology (LFT)

Watch

©2016 RespireRx Phamaceuticals Inc. All Rights Reserved.